<DOC>
	<DOC>NCT00781105</DOC>
	<brief_summary>The "Chinese PAC" study (CLDT600ACN03) will evaluate the efficacy and safety of open label telbivudine in 2,200 compensated Chronic Hepatitis B (CHB) adults. The primary objective of the study is the proportion of patients achieving undetectable HBV DNA at week 52.</brief_summary>
	<brief_title>Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male or female 16 to 65 year of age Documented CHB defined by detectable serum HBsAg and serum HBV DNA level Willing and able to comply with the study drug regimen Written informed consent before any assessment Patient has a history of/or clinical signs/symptoms of hepatic decompensation Patient has a history of HCC or findings suggestive of possible HCC Patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational at any time History of hypersensitivity to any of the drugs (telbivudine) or to drugs of similar clinical classes Patient has received IFN or other immunomodulatory treatment with 12 months before screening Previous treatment history with NRTIs Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Adult</keyword>
	<keyword>HBV DNA suppression</keyword>
	<keyword>Telbivudine</keyword>
</DOC>